Characteristic | Remission, n = 145 | Non-remission, n = 113 | p value |
---|---|---|---|
Age, yr | 55 (45, 62) | 57 (51, 67) | 0.003 |
Male, n (%) | 100 (69) | 76 (67.3) | 0.770 |
Systolic BP, mmHg | 130 (113, 140) | 131 (118.5, 142) | 0.203 |
Diastolic BP, mmHg | 79.65 ± 13.10 | 80.24 ± 15.44 | 0.089 |
Serum cholesterol, mmol/L | 6.80 (5.48, 8.28) | 6.89 (5.80, 8.64) | 0.432 |
Serum creatinine, µmol/L | 83 (68.5, 96.5) | 80 (67, 92.5) | 0.643 |
Serum albumin, g/L | 24.9 ± 5.5 | 23.8 ± 4.9 | 0.227 |
eGFR, mL/min/1.73m2 | 90.6 (71.3, 101.8) | 90.5 (72.7, 99.3) | 0.609 |
UPCR, g/g | 4.22 (3.53, 5.68) | 4.24 (3.52, 5.28) | 0.796 |
Anti-PLA2R-Ab-positive, n (%)a | 100/124 (80.6) | 67/79 (84.8) | 0.449 |
Anti-PLA2R-Ab titer, RU/ml | 41.10 (4.56, 110.63) | 70.86 (22.26, 156.34) | 0.015 |
ACE inhibitor/ARB use, n (%) | 77 (53.1) | 63 (55.8) | 0.672 |
Treatment | 0.008 | ||
CNI, n (%) | 39 (26.9) | 47 (41.6) | 0.013 |
CTX, n (%) | 47 (32.4) | 39 (34.5) | 0.723 |
RTX, n (%) | 49 (40.7) | 27 (23.9) | 0.005 |
Prior immunosuppressive therapy, n (%) | 51 (35.2) | 34 (30.1) | 0.389 |
Follow-up, mo | 15 (12, 24) | 12 (6, 15) | < 0.001 |